News

Here are highlights from the week in Psychiatric Times.

Investigational agent KarXT is a first-in-class muscarinic receptor agonist demonstrating antipsychotic efficacy and safety in short- and long-term clinical trials.

What is new in research on schizophrenia?

Social media content moderation: a brief for clinicians.

We're highlighting issues in addiction in our special Digital Supplement! Learn more here.

"Touched by the hard times, flowers shed tears. Grieved by separations, birds are startled in their hearts."

Experts shared the study results in a poster presentation at the 2024 ASCP Annual Meeting.

An expert discusses how the risks of benzodiazepine prescribing have been exaggerated in the minds of government officials, critics, and the public at large.

H. Steven Moffic, MD, interviews Neil Krishan Aggarwal, MD, MBA, MA, DFAPA, on his new book and the concept of peacemaking.

Physician-assisted suicide is now legal in 11 jurisdictions in the US. To this, several clinicians say: “We must care for the dying, not make them dead.” Learn more in our June cover story.

Andrew Krystal, MD, and Wayne Drevets, MD, share their thoughts on the recent seltorexant data presented at the 2024 ASCP Annual Meeting.

The study aims to collect data to optimize the design of the treatment’s upcoming phase 3 clinical trial.

What questions did a Milwaukee community of older adults have for a psychiatrist?

What are the connections between environmental factors and the development of mental disorders?

Psychiatric Times Editor-in-Chief shares his thoughts on the FDA Psychopharmacologic Drugs Advisory Committee decision for MDMA.

How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.

The FDA Psychopharmacologic Drugs Advisory Committee voted against recommending approval for psychedelic MDMA.

Society starts with two—one is a fiction.

Write to us now to be part of our series focused on stress and anxiety this month.

The FDA Meeting of the Psychopharmacologic Drugs Advisory Committee evaluating the New Drug Application for MDMA is happening now. How do clinicians feel about this potential treatment for PTSD?

What we need more of: generosity.

A psychiatrist reflects and laments on the state of the country.

Carmen Kosicek, MSN, PMHNP-BC, and team share their excitement over potential new options pending the FDA's Advisory Committee meeting.

Rakesh Jain, MD, shares more about the recent approval of Austedo XR for the treatment of tardive dyskinesia and Huntington disease chorea control.

Investigators have dosed the first participant in a new study investigating the neurophysiological effects of BPL-003.

A lead educator and clinical consultant in the Lykos Therapeutics MDMA Therapist Education Program discusses MDMA-assisted therapy’s potential.

Some clinicians are skeptical about the potential of MDMA-assisted therapy...

If approved, how will MDMA-assisted therapy impact clinical psychiatry? The CEO of Lykos Therapeutics shares her thoughts.

In advance of the June 4 FDA Advisory Committee Meeting on MDMA-assisted therapy, we sat down with Alejandra Alva, MD, to get his first impressions.

The importance of compassion.